La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ApicHope Pharmaceutical Bilan de santé
Santé financière contrôle des critères 5/6
ApicHope Pharmaceutical has a total shareholder equity of CN¥2.7B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 42.7%. Its total assets and total liabilities are CN¥4.7B and CN¥2.0B respectively. ApicHope Pharmaceutical's EBIT is CN¥213.8M making its interest coverage ratio 7.9. It has cash and short-term investments of CN¥605.4M.
Informations clés
42.7%
Ratio d'endettement
CN¥1.15b
Dette
Ratio de couverture des intérêts | 7.9x |
Argent liquide | CN¥605.41m |
Fonds propres | CN¥2.69b |
Total du passif | CN¥1.96b |
Total des actifs | CN¥4.65b |
Mises à jour récentes de la santé financière
Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?
Jun 27ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet
Mar 15Recent updates
Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?
Jun 27ApicHope Pharmaceutical (SZSE:300723) Is Paying Out A Larger Dividend Than Last Year
May 27ApicHope Pharmaceutical's (SZSE:300723) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Bearish: Analysts Just Cut Their ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Revenue and EPS estimates
May 02ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet
Mar 15Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings
Feb 27Analyse de la situation financière
Passif à court terme: 300723's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥1.6B).
Passif à long terme: 300723's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥395.4M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 300723's net debt to equity ratio (20.2%) is considered satisfactory.
Réduire la dette: 300723's debt to equity ratio has increased from 0.04% to 42.7% over the past 5 years.
Couverture de la dette: 300723's debt is well covered by operating cash flow (41.7%).
Couverture des intérêts: 300723's interest payments on its debt are well covered by EBIT (7.9x coverage).